3 blue chip bargains you can’t afford to miss!

Royston Wild looks at three FTSE 100 (INDEXFTSE: UKX) stars dealing far too cheaply at current prices.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 (INDEXFTSE: UKX) cut-price flyer easyJet (LSE: EZJ) continues to toil as investors digest the possible impact of Brexit on future revenues.

Brokers have taken the red pen to their earnings forecasts in recent weeks, prompted by profit warnings in the wake of the referendum. Consequently easyJet is now expected to endure a 22% bottom-line slide in the year to September 2016, breaking the firm’s long-running record of meaty earnings growth.

However, this leaves the Luton business dealing on a meagre P/E rating of 9.6 times, suggesting that the risks facing easyJet are more than priced-in at present.

While tough economic conditions in the UK have muddied the waters, I reckon surging traffic elsewhere — aided by easyJet’s steady route expansion programme on the continent — should underpin excellent long-term sales expansion. Indeed, the company moved 7.6m passengers in July, up 6.7% year-on-year.

And a brilliant 5.1% dividend yield, smashing the blue chip average of 3.5%, underlines easyJet’s position as a great value contrarian pick, in my opinion.

Parcels powerhouse

Packages giant Royal Mail (LSE: RMG) is also suffering following June’s EU referendum as the prospect of a lengthy recession — and with it significant pressure on consumer spending habits — hangs in the air.

This would of course have a huge impact on parcel volumes at Royal Mail, the company benefitting in recent times from the breakneck growth of online shopping.

I believe there’s still plenty of reason to be optimistic, however. Indeed, the likelihood of significant discounting by retailers should stop parcel activity falling off a cliff. Meanwhile, Royal Mail’s GLS European division should take some of the sting out of any immediate problems in its core markets.

A P/E rating of 12.3 times for the year to March 2017, created by an anticipated 1% earnings uptick, certainly suggests good value in my opinion. And a dividend yield of 4.5% puts the icing on the cake.

The right medicine

On paper, GlaxoSmithKline (LSE: GSK) doesn’t fall within the usual parameters associated with top value stocks.

For 2016 the drugs developer is expected to bask in a 27% earnings surge. But this results in a P/E multiple of 17.4 times, falling outside the FTSE 100 average of 15 times.

I reckon GlaxoSmithKline is still great value at this price however, particularly as 2016 is likely to prove a watershed in the firm’s growth story. The company has seen earnings collapse in each of the past four years as patent expirations in sales-driving labels have weighed.

But huge investment in fast-growing therapy areas like vaccines, helped by shrewd acquisitions and joint ventures in recent years, has transformed GlaxoSmithKline’s revenues outlook for the coming years. And I expect accelerating healthcare spending in emerging markets to drive earnings still higher.

Meanwhile, a planned 80p per share dividend — yielding a handsome 4.8% — offsets GlaxoSmithKline’s slightly-toppy earnings ratio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 discounted US stock for me to buy for the cybersecurity revolution!

This AI-powered cybersecurity company's beating its rival technologies, and a recent share price drop may have just created a buying…

Read more »

Investing Articles

Buying 1,019 shares of this FTSE 100 monopoly could earn me £2,284 in passive income

National Grid’s monopoly status makes it a popular passive income stock. But investors shouldn’t underestimate the risks that come with…

Read more »

Investing Articles

£5k in savings? Here’s how I’d aim to build a rising passive income of £5,500 a month

Harvey Jones invests in FTSE 100 dividend stocks with the aim of generating a growing passive income to fund his…

Read more »

Investing Articles

Are these 2 legendary dividend stocks worth buying and holding until 2030?

Zaven Boyrazian explores two of the UK's most legendary dividend stocks with tremendous track records. But are they good long-term…

Read more »

Investing Articles

I’d listen to Warren Buffett’s advice and buy undervalued shares today

Warren Buffett’s focus on quality at a reasonable price has proven to be a highly lucrative strategy that other investors…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

How I’d aim to turn an empty ISA into a £50k second income!

Zaven Boyrazian outlines how investors can target a £50,000 second income starting with a brand new ISA while also keeping…

Read more »

Investing Articles

Up 202%! This hidden FTSE gem has outpaced the Rolls-Royce share price and is still climbing!

The Rolls-Royce share price may have outpaced every FTSE 100 rival over the last couple of years but Harvey Jones…

Read more »

Investing Articles

How I’d invest my first £1,000 in a SIPP

Investing the first £1,000 in an SIPP can be a daunting process, especially for new investors. Zaven Boyrazian explains what…

Read more »